Vaxcyte, Inc. (PCVX) stock

PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30

$63.37−1.32 (-2.04%)

Close on Nov 13, 2026Market cap $9.43BP/E –Yield 0.00%

Vaxcyte revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Vaxcyte has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?